CanniMed Therapeutics Inc (TSE:CMED) Closes In Red


In the last trading session, the stock price of CanniMed Therapeutics Inc (TSE:CMED) declined more than 2% to close the day at CAD$10.84. The decline came at a share volume of 37,164 compared to average share volume of 83,755. After the recent decline the market cap of firm stands at over $237 million. There appears no apparent reason that triggered this decline in yesterday’s trading session.

The highlights

Earlier this year, CanniMed reported test data for some of its offerings online to showcase they were free of prohibited. A few weeks later, Aurora Cannabis Inc (CVE:ACB), which issued a recall for its bulk shipment it bought from Organigram, reported it would commence testing products and announcing the results online for customers to inspect. Soon after, the CCA, which showcases 15 federally approved firms, stated it would follow trend with a similar measure.

The reason behind this all discussion comes on the base that as of now there are no uniform official measures framed to ensure customer safety in the industry. In the meantime, numerous patients have informed The Globe they felt ill from exposure to the tainted offerings, and now suffer persistent pain, breathing difficulty, nausea and rashes, headaches, among other issues. In such a scenario, CanniMed report brings a relief for its customers who were perturbed following the stories of tainted products.

The recalls from other firms have raised troubling concerns about Health Canada’s inaccuracy of the sector, mainly as the federal government prepares to approve cannabis for recreational use in 2018. Although the federal government has hyped the approved manufacturers as safe, medical-grade offering, Health Canada accepted to The Globe that it was assessing those firms to check that they weren’t using unsafe chemicals to benefit their crops.

CanniMed is one company in the sector that has been recording significant month-over-month growth in volume of medicinal cannabis shipped and addition of new patients.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.